<DOC>
	<DOC>NCT00152919</DOC>
	<brief_summary>Swelling of the prostate can occur during and after a brachytherapy. This swelling can cause urinary problems ranging from difficulty voiding to urinary retention. The purpose of this study is to investigate whether Mobicox started one week before brachytherapy and then continued afterwards is more effective in reducing the risk of needing a catheter than Mobicox given only afterwards.</brief_summary>
	<brief_title>Mobicox: Study of Meloxicam to Reduce Prostate Swelling in Permanent Seed Prostate Brachytherapy</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Meloxicam</mesh_term>
	<criteria>Eligible to receive prostate brachytherapy as per the Ontario Provincial Guidelines will be eligible for this study (i.e. prostate specific antigen [PSA] &lt; 10, Gleason score &lt;7, Stage &lt;= T2a) Patients already taking antiinflammatory drugs Patients with allergictype reactions, including asthma and urticaria, to aspirin or nonsteroidal antiinflammatory agents (see product information)</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
</DOC>